At El Paso Eye Surgeons, P.A., we are dedicated to providing the most technologically advanced therapy both on the market and currently under investigation. Because of our vast surgical experience, we have been invited to participate in a number of clinical trials. We are a part of a number of ongoing Food and Drug Administration Phase 3 clinical trials as well as industry sponsored trials, and observational studies. We are also actively involved in sharing our own clinical outcomes worldwide via publication in peer-reviewed medical literature and major ophthalmic national and international conferences. We will be happy to answer any questions you may have about regarding our current or previous research. For information, please feel free to contact our research coordinator via the contact form below via phone at 915-542-0279.

GLAUCOMA

Elios Vision, Inc. EP-02: A prospective, multicenter, non-randomized clinical trial designed to evaluate the safety and feasability of the ELIOS System to reduce intraocular pressure in patients with primary open-angle glaucoma as a standalone procedure. 

Glaukos Corporation GLK-101-01 WCG IRB Protocol #20233842: Multicenter, randomized, double-masked trial to evaluate the safety and efficacy of iDose® TR (travopost intraocular implant) in conjunction with the placement of iStent infinite vs. iStent infinite alone in subjects with open-angle glaucoma or ocular hypertension.

Ivantais study GLD122c-C001: Summit VII Study for Hydrus Microstent implantation. A multi-center, prospective, phase III clinical trial evaluating efficacy and safety of Hydrus Microstent implantation in patients with refractory glaucoma. Principal investigator.

iStar REC-233 Version 8.0 WCG IRB Protocol #20213339: A prospective, multicenter masked clinical trial to evaluate the safety and effectiveness of the Miniject CS627 Implant in subjects with open angle glaucoma.

Alcon study GLP489‐C001: A multi-center, prospective, phase III clinical trial evaluating the safety and efficacy study of the CyPass Micro-Stent in Pseudophakic Patients with Mild to Moderate Open Angle Glaucoma. Principal investigator.

Alcon study GLD122c-C001: An FDA, post-approval, prospective study evaluating safety of the CyPass Micro-Stent in combination with cataract surgery with mild to moderate open angle glaucoma, evaluation of safety and efficacy. Principal investigator.

Alcon study ILR431b-P001: Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs evaluating post-operative inflammation. Principal investigator.

Allergan XEN-GPS study (CMO-US-EYE-0600). A multicenter, randomized study comparing safety and efficacy of the Xen45 gel implant versus trabeculectomy.

Equinox CP-010. The safety and effectiveness of negative pressure applied by the Equinox Mercury™ multi-pressure dial to lower intraocular pressure (IOP) in adult subjects (The Apollo Study). Principle investigator

Glaukos® GC – 011 iStent infinite™ study. A prospective, multicenter, non-comparative evaluating the safety and efficacy of the iStent infinite as a stand-alone procedure in patients with refractory open angle glaucoma. Principle investigator

Glaukos study GC012: A multi-center, prospective, randomized phase III clinical trail evaluating two models of the iDose delivery system with two different travoprost elution rates, compared to topical timolol ophthalmic solution, 0.5%.

Sight Sciences Gemini OMNI Study (NCT03861169): A multi-center, prospective, non-randomized, controlled clinical study evaluation of the safety and effectiveness of the OMNI Viscosurgical System in Canaloplasty with focal goniotomy in the Reduction of IOP in Primary Open Angle Glaucoma. Principal investigator

Sight Sciences study SIGHTVISCO-001: A Multi-Center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO 360 Viscosurgical System in Canaloplasty versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma